Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 2, 2000, Pages 625-633

  Kim, Saejeong ^a   Westphalen, Robert ^a   Callahan, Brian ^a   Hatzidimitriou, George ^a   Yuan, Jie ^a   Ricaurte, George A ^a,b  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 1 METHYL 4 PHENYLPYRIDINIUM; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMFEBUTAMONE; COCAINE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; METHAMPHETAMINE; METHYLPHENIDATE; NEUROTOXIN; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG MECHANISM; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPTOSOME;

ANIMALS; COCAINE; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FENFLURAMINE; GLUTAMIC ACID; KINETICS; MALE; METHAMPHETAMINE; NEOSTRIATUM; PRESYNAPTIC TERMINALS; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; SYNAPTOSOMES; TEMPERATURE; TIME FACTORS;

EID: 0034091978     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Albers DS and Sonsalla PK (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275:1104-1114.
2. Ali SF, Newport GD and Slikker W Jr (1996) Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents. Ann NY Acad Sci 801:187-198.
3. Axt KJ, Commins, Vosmer G and Seiden LS (1990) α-Methyl-p-tyrosine pretreatment partially prevents methamphetamine-induced endogenous neurotoxin formation. Brain Res 515:269-276.
4. Batchelor M and Schenk JO (1998) Protein kinase A activity may kinetically up-regulate the striatal transporter for dopamine. J Neurosci 18:10304-10309.
5. Bennett BA, Hollingsworth CK, Martin and Harp JJ (1998) Methamphetamine-induced alterations in dopamine transporter function. Brain Res 782:219-227.
6. Bennett BA, Hyde CE, Pecora JR and Clodfelter JE (1993) Differing neurotoxic potencies of methamphetamine, mazindol, and cocaine in mesencephalic cultures. J Neurochem 60:1444-1452.
7. Berman SB, Zigmond MJ and Hastings TG (1996) Modification of dopamine transporter function: Effect of reactive oxygen species and dopamine. J Neurochem 67:593-600.
8. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W Jr and Holson RR (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268:1571.
9. Bowyer JF, Tank AW, Newport GD, Slikker W Jr, Ali SF and Holson RR (1992) The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in striatum. J Pharmacol Exp Ther 260:817-824.
10. Cadet JL, Sheng P, Ali S, Rothman R, Carlson E and Epstein CJ (1994) Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem 62:380-383.
11. Cubells JF, Rayport S, Rajindron G and Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular stress. J Neurosci 14:2260-2771.
12. De Vito MJ and Wagner GC (1989) Methamphetamine-induced neuronal damage: A possible role for free radicals. Neuropharmacology 28:1145.
13. Elayan I, Gibb JW, Hanson GR, Foltz RL, Lim HK and Johnson M (1992) Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphatamine but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxyamphetamine. Eur J Pharmacol 221:281-288.
14. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW and Hanson GR (1997a) Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282:834-838.
15. Fleckenstein AE, Wilkins DG, Gibb JW and Hanson GR (1997b) Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther 283:281.
16. Fukumura M, Cappon G, Cunfeng P, Broening H and Vorhees C (1998) A single dose model of methamphetamine-induced neurotoxicity in rats: Effects on neostratal monoamines and glial fibrillary acidic protein. Brain Res 806:1-7.
17. Fumagalli F, Gainetdinov RR, Valenzano KJ and Caron MG (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter. J Neurosci 18:4861.
18. Gibb JW, Hanson GR and Johnson M (1994) Neurochemical mechanisms of toxicity, in Amphetamine and Its Analogs - Psychopharmacology, Toxicology and Abuse (Cho AK and Segal DS eds) pp 269-295, Academic Press, New York.
19. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
20. Gray EG and Whittaker VP (1962) The isolation of nerve endings from brain: An electron microscopic study of cell fragments derived by homogenization and centrifugation. J Anat 96:79-87.
21. Hotchkiss AJ, Morgan ME and Gibb JW (1979) The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci 25:1373.
22. Huang NK, Wan FJ, Tseng CJ and Tung CS (1997) Amphetamine induces hydroxyl radical formation in the striatum of rats. Life Sci 61:2219-2229.
23. Johnson M, Elayan I, Hanson GR, Foltz RI, Gibb JW and Lim HK (1992) Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central seretonergic and dopaminergic systems. J Pharmacol Exp Ther 261:447-453.
24. Karoum F, Chrapusta SJ, Egan MF and Wyatt RJ (1993) Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: A mass fragmentographic study. J Neurochem 61:1369-1375.
25. Kogan FJ, Nichols WK and Gibb JW (1976) Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur J Pharmacol 38:363-371.
26. Lowry OH, Rosenbrough NJ, Farr AL and Randall RJ (1951) Protein measurements with Folin phenol reagent. J Biol Chem 193:265-275.
27. Marek GJ, Vosmer G and Seiden LS (1990a) The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat. Brain Res 516:1-7.
28. Marek GJ, Vosmer G and Seiden LS (1990b) Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res 513:274.
29. Matsuda IA, Hanson GR and Gibb JW (1989) Neurochemical effects of amphetamine metabolites on central dopaminergic and serotonergic systems. J Pharmacol Exp Ther 251:901-908.
30. Michel PP and Hefti F (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26:428-435.
31. O'Callaghan JP and Miller D (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
32. Olanow CW and Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. Ann Rev Neurosci 22:123-144.
33. Park TH and Mytilineou C (1992) Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP + -damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF. Brain Res 599:83-87.
34. Rollema H, De Vries JB, Westernick BHC, Van Putten FMS and Horn AS (1986) Failure to detect 6-hydroxydopamine in rat striatum after the dopamine releasing drugs dexamphetamine, methyl amphetamine and MPTP. Eur J Pharmacol 132: 65-69.
35. Schuster CR, Lewis M and Seiden LS (1986) Fenfluramine: Neurotoxicity. Psychopharmacol Bull 22:148-151.
36. Seiden LS, Fischman MW and Schuster CR (1976) Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1:215-219.
37. Seiden LS and Vosmer G (1984) Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol Biochem Behav 21:29.
38. Sonsalla PK, Nicklas WJ and Heikkila RE (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science (Wash DC) 243:398-400.
39. Sonsalla PK, Riordan DE and Heikkila RE (1991) Competitive and non-competitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J Pharmacol Exp Ther 256:506-512.
40. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18: 419-427.
41. Wagner GC, Lucot JB, Schuster CR and Seiden LS (1983) Alpha-Methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res 270:285.
42. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ and Westley J (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181:151.
43. Yamamoto BK and Zhu W (1998) The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther 287:107-114.
44. Zhang L, Coffey LL and Reith MEA (1997) Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem Pharmacol 677:677-688.
45. Zhang L and Reith MEA (1996) Regulation of the functional activity of the human dopamine transporter by the arachidonic acid pathway. Eur J Pharmacol 315: 345-354.
46. Zhao Z, Castagnoli N, Ricaurte GA, Steele T and Martello MB (1992) Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin, 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl]propane [(methylenedioxy)methamphetamine]. Chem Res Toxicol 5:89-94.